ArticleAmerican journal of hematology2026
A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).
Kenneth I Ataga et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.